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1  | INTRODUCTION
Venous	thromboembolism	(VTE),	comprising	deep	vein	thrombosis	









is	 independent	 of	 the	 severity	 or	 clot	 burden	 of	 the	 thrombotic	
event.3,4	Some	may	develop	what	has	been	termed	postthrombotic 
panic syndrome	 with	 persistent	 symptoms	 meeting	 the	 diagnostic	
criteria	for	posttraumatic	stress	disorder.5
Studies	initially	undertaken	to	evaluate	the	experiences	of	CAT	
patients	 of	 self‐injecting	 low‐molecular‐weight	 heparin	 (LMWH),	
identified	 a	 significant	 level	 of	 distress	 and	 anxiety	 associated	





ing	 experience,	 with	 limited	 support	 or	 information,	 in	 complete	
juxtaposition	 with	 the	 treatment	 they	 received	 for	 their	 cancer.	




(PELICANOS),	 was	 reported	 from	 Spain;	 a	 country	with	 a	 similar	



















through	 public	 funding,	with	 the	 remainder	 covered	 by	 health	 in‐






















sampling	 of	 patients	 attending	 a	 thrombosis	 outpatient	 service	 at	
a	university‐affiliated	teaching	hospital,	which	serves	a	population	
of	2.3	million,	were	sequentially	screened	for	inclusion	in	the	study.	
Screening	was	 undertaken	 by	 experienced	 thrombosis	 nurses	 (JS,	
AB,	 and	 KS),	 who	 also	 approached	 eligible	 patients	 face	 to	 face.	
Where	patients	attended	with	their	partner	or	next	of	kin,	they	were	
also	given	an	opportunity	to	be	interviewed.
English‐speaking	 participants	 were	 eligible	 if	 they	 had	 histo‐
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All	participants	provided	 informed	written	consent.	Each	 inter‐
view	was	 individually	 conducted	by	1	of	3	 researchers	 (JS,	AB,	or	










were	 experienced	 in	 communication	 skills	 but	were	 new	 to	 quali‐
tative	interviewing.	They	received	interview	training	from	the	chief	
investigator	 (SN)	 and	 undertook	 pilot	 interviews	 with	 feedback.	
Interviews	were	audio	recorded	and	transcribed	verbatim.	The	chief	
investigator	 reviewed	 each	 interview,	 and	 feedback	 was	 given	 to	
further	hone	the	interviewer's	skills.	Interviews	were	conducted	at	
the	preferred	 location	of	 the	patient:	either	 the	patient's	home	or	
a	hospital	outpatient	clinic.	Questions	were	guided	by	an	interview	






To	 facilitate	 this,	 questions	 were	 open‐ended,	 with	 the	 use	 of	
prompts	 to	 probe	 further	 into	 issues	 that	 arose	 as	 significant	 or	





Transcripts	 were	 typed	 into	 a	 Word	 document,	 and	 data	 were	
managed	 using	 NVivo	 10	 computer	 software	 (QSR	 International,	
Melbourne,	 Australia).11	 Any	 identifying	 information	 was	 an‐
onymized.	Data	analysis	was	undertaken	using	Framework	Analysis	
as	 per	 the	 previous	 study	 using	 Richie	 and	 Spencer's	 5	 intercon‐











This	 was	 done	 in	 order	 to	 explicate	 potential	 cultural	 and	 opera‐
tional	differences	that	were	not	apparent	in	the	UK	and	Spanish	data	








Research	 ethics	 approval	 was	 obtained	 from	 the	 University	 of	
British	Columbia	BC	Cancer	Research	Ethics	Board	(H14‐01898)	
before	 study	 enrollment.	 Twenty	 patients	 agreed	 to	 partici‐
pate,	 and	 their	 clinical	 characteristics	 are	 recorded	 in	 Table	 1.	
Three	patients	who	were	approached	declined	to	participate	but	
gave	 no	 reason.	 No	 interviews	 needed	 repeating,	 and	 no	 par‐
ticipants	requested	transcripts	to	review.	Theoretical	saturation	
was	 reached	 at	 14	 interviews,	 when	 no	 new	 themes	 were	 ap‐
parent.	The	3	major	themes	previously	identified	in	the	original	
PELICAN	 and	 PELICANOS	 studies	 were	 also	 observed	 in	 this	
data	 set,	 namely,	 the	 distressing	 experience	 of	 CAT,	 informa‐
tion	 requirements,	 and	 adaptive	 behaviors/ritualization8,9. In 
addition,	 2	 new	 themes	 emerged:	 incidental	 pulmonary	 emboli	
and	 the	 cost	 implications	 of	 LMWH.	 These	 are	 summarized	 in	
Figure	1.	Each	theme	is	discussed	below	with	its	associated	sub‐
themes.	 Themes	 are	 supported	 by	 patient	 quotes,	 which	were	
chosen	according	 to	2	 criteria:	 They	 illustrate	 the	 theme	being	
discussed,	and	they	represent	a	breadth	of	data	across	as	many	
participants	as	possible.
3.1 | Previously identified theme: Traumatic 
nature of CAT








cess.	 In	 PELICANADA,	 patients	 found	 the	 delivery	 of	 the	 diagno‐
sis	of	CAT	to	be	rushed,	and	the	fact	that	CAT	was	potentially	 life	
threatening	exacerbated	their	distress.
Well,	 at	 first	 it	made	me	 feel	 that	my	 health	 issues	
were	even	more	terminal	than	the	cancer	originally.	
100‐03
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3.2 | Previously identified theme: Information needs
Patients	 identified	2	main	areas	of	 information	need.	First,	 lack	of	
forewarning	regarding	the	risk	of	clots	and	possibility	of	death	was	
a	significant	driver	of	distress.	They	also	worried	regarding	the	un‐
certainty	of	whether	 a	 clot	may	 recur.	Patients	 felt	 that	 adequate	
forewarning	and	information	would	help	ameliorate	this.
The	blood	clot	was	a	scary	thing	because	I	didn’t	know	
if	 I	 should	 have	 been	 looking	 for	 something	 and	 from	















Some	 patients	 received	 no	 information	 on	 how	 to	 inject,	which	
often	led	to	poor	technique	and	associated	complications.
My	stomach	was	so	bruised	 that	 I	didn’t	do	 the	 top	
part	of	my	belly	because	nobody	ever	told	me	(to	do)	











TA B L E  1  Characteristics	of	study	participants
Code Age
Sex





100‐1 65 M Myeloma Palliative DVT WarfarinLMWH 12 Self
100‐2 62 F Lung Post	curative	resection PE LMWH 9 Self
100‐3 72 M Metastatic	Prostate Palliative iPE LMWH 5 Self
100‐4 74 M Prostate Curative iPE LMWH 12 Self
100‐5 68 F Metastatic	Breast Palliative iPE LMWH 7 Self
100‐8 62 F Metastatic	Ovarian Palliative PE LMWH 9 Self
100‐9 55 F Metastatic	colorectal Palliative Stroke LMWH 8 Self
100‐10 71 F Chronic	Lymphocytic	
Leukemia
Post	stem	cell	transplant iPEiDVT LMWH 5 Self
100‐11 69 F Renal cell carcinoma Palliative iDVT Warfarin 11 Self
100‐12 68 F Metastatic	breast Palliative PE LMWH 6 Self
100‐13 49 M Metastatic	colorectal Palliative PE LMWH 14 Self
100‐14 67 M Gastric Metastatic PEDVT LMWH 3 Self
100‐15 65 F Breast Metastatic PE LMWH 4 Wife
100‐16 68 F Bladder Curative DVT LMWH 9 Daughter
100‐17 69 M Myeloma Post	stem	cell	transplant DVT LMWH 5 Self
100‐18 70 F Acute	myeloid	leukemia In	remission PE LMWH 6 Husband
100‐19 48 F Metastatic	ovarian Palliative iPE LMWH 6 Self
100‐20 63 F Myeloma In	remission,	on	maintenance	
treatment
DVT LMWH 8 Husband
100‐21 39 M Acute	myeloid	leukemia Post	stem	cell	transplant DVT LMWH 4 Self
100‐22 58 F Brain Inoperable,	palliative	chemo DVT LMWH 6 Self
DVT,	deep	vein	thrombosis;	iDVT,	incidental	deep	vein	thrombosis;	iPE,	incidental	pulmonary	embolus;	LMWH,	low‐molecular‐weight	heparin;	PE,	
pulmonary	embolus;	VTE,	venous	thromboembolism.




Patients	 and	 caregivers	 were	 willing	 to	 learn	 to	 self‐inject,	













We	 have	 our	 coffee	 and	 our	muffin	 in	 the	morning	
and	it’s	time	for	my	shot.	We	do	it	every	day.	…	Then	I	
hold	it	there,	hold	the	little	pad	over	it	and,	for	about	
5	minutes,	 have	my	 second	 cup	of	 coffee	 and	done	
for	the	day.	
100‐04
I	 do	 it	 in	 the	 morning,	 and	 then	 I	 am	 good	 for	 the	
whole day. 
100‐05
3.4 | New theme: Incidental PE
Incidental	 pulmonary	 emboli	 (iPE)	 are	 clots	 that	 are	 diagnosed	on	
imaging	ordered	for	indications	other	than	PE.	These	usually	occur	
when	 staging	 a	 newly	 diagnosed	 cancer	 or	 when	 evaluating	 re‐
sponse	to	treatment.	Generally,	these	patients	do	not	spontaneously	



































3.5 | New theme: Access to medicines
The	cost	of	 LMWH	for	 the	 treatment	of	CAT	was	covered	by	 the	
provincial	 health	 care	plan	 (PharmaCare)	 for	 periods	of	 6	months,	





















PharmaCare	 coverage.	 Where	 patients	 did	 not	 have	 appropriate	



















from	 the	 United	 Kingdom	 and	 Spain	 have	 identified	 CAT	 to	 be	 a	







iety	 for	 the	 patient	 because	 imaging	was	 ordered	 either	 to	 stage	
a	 recently	 diagnosed	 new	 cancer	 or	 to	 assess	 response	 to	 recent	
treatment.	As	previous	studies	have	 illustrated,	one	of	 the	drivers	
of	 distress	 around	 CAT	 is	 living	 with	 a	 potentially	 fatal	 condition	
that	carries	an	ongoing	risk	of	recurrence.7‒9	Breaking	the	news	to	
a	cancer	patient,	already	contemplating	their	mortality	while	wait‐
ing	 anxiously	 for	 their	 staging	 results,	 that	 they	 have	 developed	
another	potential	threat	to	life	should	be	afforded	the	same	sensi‐
tive	approach	of	any	other	breaking	bad	news	scenario.	In	practice,	
this	 rarely	happens;	 instead,	 learning	 the	 findings	 from	a	stranger,	
by	 telephone,	without	 the	benefit	of	a	 supportive	environment	or	
customary	approach	to	breaking	bad	news,	is	the	norm.	Patients	re‐







tation	 of	 a	 clinical	 pathway	 for	 the	 diagnosis	 and	management	 of	
iPE,	which	 includes	 consideration	of	 information	delivery	with	 re‐
spect	to	both	diagnosis	of	the	PE	and	its	ongoing	management.	Such	
pathways	 do	 exist	 but	 arguably	 should	 be	 a	minimum	 standard	 in	
CAT	management.14	 It	 is	 important	 to	note	 that	 the	 issues	around	
the	diagnosis	of	iPE	are	probably	not	specific	to	Canada;	it	is	more	
likely	 a	 reflection	of	 the	numbers	of	 iPE	patients	 in	PELICAN	and	
PELICANOS	being	 too	 low	for	any	meaningful	 signal	 to	emerge	 in	












(24.1%).17	 In	 an	earlier	observational	 study,	only	19%	of	American	
patients	with	CAT	received	LMWH	first	line,	and	81%	warfarin.	The	
most	common	 reason	given	by	patients	 receiving	warfarin	 (49.4%)	







As	with	 all	 studies,	 it	 is	 important	 to	 consider	 the	 data	within	
the	context	of	the	study	limitations.	Interviews	were	conducted	by	
3	 researchers	 (JS,	AB,	 and	KS),	which	could	potentially	 lead	 to	 in‐













of	 CAT	 diagnosis,	 and	 acceptability	 of	 LMWH.	 The	 emergence	 of	
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